Akebia Therapeutics (STU:AX9) Beginning Cash Position : €41.0 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Beginning Cash Position?

Akebia Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2024 was €41.0 Mil.

Akebia Therapeutics's quarterly Beginning Cash Position declined from Sep. 2023 (€51.8 Mil) to Dec. 2023 (€44.2 Mil) and declined from Dec. 2023 (€44.2 Mil) to Mar. 2024 (€41.0 Mil).

Akebia Therapeutics's annual Beginning Cash Position declined from Dec. 2021 (€204.6 Mil) to Dec. 2022 (€143.3 Mil) and declined from Dec. 2022 (€143.3 Mil) to Dec. 2023 (€85.4 Mil).

Akebia Therapeutics Beginning Cash Position Historical Data

The historical data trend for Akebia Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Beginning Cash Position Chart

Akebia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

96.39

123.14

204.55

143.34

85.44

Akebia Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															87.02	55.07	51.81	44.18	41.01

Akebia Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Akebia Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (STU:AX9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (STU:AX9) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

AKBA:USA AX9:Germany

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (STU:AX9) Headlines

No Headlines